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Spatial intensity distribution analysis (SpIDA) is a recently developed approach
for determining quaternary structure information on fluorophore-labelled pro-
teins of interest in situ. It can be applied to live or fixed cells and native tissue.
Using confocal images, SpIDA generates fluorescence intensity histograms
that are analysed by super-Poissonian distribution functions to obtain density
and quantal brightness values of the fluorophore-labelled protein of interest.
This allows both expression level and oligomerisation state of the protein to be
determined. We describe the application of SpIDA to investigate the oligomeric
state of G protein-coupled receptors (GPCRs) at steady state and following
cellular challenge, and consider how SpIDA may be used to explore GPCR
quaternary organisation in pathophysiology and to stratify medicines.
SpIDA: An Approach to Detect Protein Oligomerisation State
Spatial intensity distribution analysis (SpIDA) (see Glossary) is a recently developed
biophysical approach to interrogate the organisational structure of proteins of interest in situ
[1–4]. SpIDA is based on the generation of pixel-integrated fluorescence intensity histograms,
created from regions of interest (RoIs) drawn on recorded confocal images, which are analysed
with super-Poissonian distribution functions to obtain density maps and quantal bright-
ness (QB) values of the fluorophoreused to label the protein being studied. Normalisation of these
values to the QB of the fluorophore label in its monomeric state provides information on both the
density (usually expressed as particles per mm2) and the oligomeric state (expressed as mono-
meric equivalent units, MEUs) of the assessed protein. Here, the advantages and the limitations of
SpIDA when compared with other biophysical approaches are briefly considered. This is followed
by a description of the use of SpIDA to investigate the oligomeric state of rhodopsin-like (class A)
[5–7], secretin-family (class B) [8], and glutamate-like (class C) [1] G protein-coupled receptors
(GPCRs) and how this may be modulated by receptor expression level and altered by treatment of
cells expressing these receptors with antagonist and inverse agonist ligands. Box 1 and
Figure 1 provide brief overviews of key steps necessary to establish and analyse SpIDA measure-
ments. A fuller description of technical aspects of SpIDA is available in Ward et al. [9].
Advantages and Limitations of SpIDA for Quantification of Protein
Oligomeric State
SpIDA was developed in response to limitations of other techniques, including fluorescence
correlation spectroscopy (FCS) and photon counting histogram (PCH), used to investigate
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GPCRs may exist and function as
monomers: however, abundant evi-
dence suggests they can form
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This concept has implications for drug
discovery as it may offer opportunities
to modulate the effects of known phar-
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protein quaternary structure. These techniques base analysis upon temporal fluorescence
fluctuations and require that the density and oligomerisation state of the protein in question
remains constant during image acquisition [3]. By contrast, SpIDA is based upon a spatial
domain fluctuation, recorded as single images representing moments in time of receptor
density and oligomerisation state. A significant advantage of SpIDA is that there is less
susceptibility to potential effects of photobleaching because only a single input image is
required, and hence, underestimation of QB and thus the size of protein complexes as such
effects are minimised [3].
An important technical challenge when using fluorescent labels in the determination of protein
oligomerisation state is that of subquantitative and therefore, imperfect, labelling (which also
applies equally to other approaches). This may be due, for example, to misfolding of a fluorescent
protein or inefficient covalent incorporation of a fluorophore or antibody-mediated addition of a
fluorescent species. Clearly, this will bias the distribution of oligomeric states measured within a
cellular system. To alleviate such concerns Godin and co-workers [10] developed the SpIDA
software to include a probability-weighted correction algorithm for nonemitting labels that can be
applied when performing SpIDA to correct for nonquantitative labelling.
A limitation of SpIDA is its inability to directly quantify rapid, real-time temporal dynamic diffusion
information relating to oligomeric complex formation or dissociation within cellular compartments,
including the plasma membrane. Moreover, dynamic protein oligomeric complex formation occurs
on a spatial resolution distance scale <100 nm and this separation distance is too small to be
resolved by conventional diffraction-limited fluorescence microscopy. To circumvent this limitation,
the laser spot confocal volume is oversampled and the excitation illumination volume for membrane
oligomerisation measurements is quantified as a surface as opposed to a 3D volume [5–9].
Use of SpIDA to Define the Quaternary Structure of GPCRs
That single-polypeptide GPCRs can form and function as dimers and/or higher-order oligom-
ers, rather than simply as monomers, has been hypothesised and then tested over a period of
many years [11]. For example, it is clear that formation of either homo- or heterocomplexes
Glossary
Agonist: chemical species that
binds to a receptor and activates it,
eliciting a biological response.
Antagonist: chemical species that
binds to a receptor preventing
activation by an agonist.
Basolateral membrane: applied
here to adherent cells in culture and
refers to the part of the membrane in
contact with the growing surface, in
this case a glass coverslip.
Laser scanning confocal
microscope images: technique for
recording optical sections through a
fluorescently labelled sample using
laser illumination to excite the sample
and a pinhole to exclude out of focus
light.
Dopamine receptors: class A
GPCRs whose primary endogenous
ligand is the neurotransmitter
dopamine. They are involved in many
neurological processes, including
motivation, pleasure, memory,
learning, and fine motor control.
Flp-In T-REx 293 cells: inducible
expression system in which a cDNA
construct of interest is integrated into
a defined locus in the genome, under
the control of the tet repressor.
Addition of tetracycline (or the more
stable doxycycline) binds the tet
repressor protein allowing protein
expression from the integrated
construct.
G protein-coupled receptor
(GPCR): integral membrane protein
able to transmit a signal across the
cell membrane in response to an
external stimulus, to activate (usually)
heterotrimeric guanine nucleotide
binding proteins (G-proteins).
Characterised by a conserved
structure comprising seven helical
membrane-spanning domains, an
extracellular N terminus, three
external loops, three internal loops,
and an internal C-terminal domain.
Subdivided into classes based upon
structural relatedness.
Inverse agonist: chemical species
that binds to a receptor and reduces
its ligand independent or constitutive
activity.
Monomeric enhanced GFP
(mEGFP): GFP isolated from the
jellyfish Aequorea victoria, mutated to
enhance stability and brightness and
ensure monomeric character
(A206K). It may be fused to proteins
of interest as a label allowing
visualisation of the cellular location of
the protein of interest.
Box 1. Important Steps to Perform SpIDA Measurements
Before starting to collect laser scanning confocal microscope images, it is necessary to determine certain values
specific to the microscope setup in use, such as the laser spot beam waist radius size, to determine the confocal spot
resolution, and detector shot noise, to ensure that only the fluorescent intensity fluctuations originating from the excited
fluorophore tag are analysed. Recommended image collection parameters for performing SpIDA are detailed in Ward
et al. [9].
Another critical step is to determine the QB of the fluorescent label that is used to tag the receptor of interest. This
requires expression in both a cellular system in which the label is expressed in defined monomeric/dimeric forms and,
importantly, in the same cellular compartment as the protein of interest; for example, for GPCR studies, at the plasma
membrane. In work described by the authors [5–8,40] this has been achieved in two distinct ways (Figure I). In the first a
single copy of monomeric EGFP, or a tandem of monomeric EGFP, was fused to the intracellular carboxyl terminus of
the single TM, integral membrane protein, CD86. Many studies, using a variety of techniques, have shown CD86 to be
strictly monomeric. When expressed, CD86–EGFP is targeted to the plasma membrane. Alternatively, both single and
tandem forms of monomeric EGFP were modified at the N terminus by addition of a consensus sequence, derived from
the Lyn non-receptor tyrosine kinase N terminus, that resulted in the co- and post-translational addition of the fatty acids
palmitate and myristate. Such dual modification is known to anchor otherwise soluble proteins to the plasma
membrane. As the C-terminal region of GPCRs is intracellular, then a copy of monomeric EGFP linked in-frame is
anticipated to be in an environment akin to that within the control constructs. Initial studies demonstrated that the
tandem forms of monomeric EGFP had QB almost exactly twice the value of the single monomeric EGFP linked forms.
Once QB has been calculated for the monomeric/dimeric controls these values are used to normalise experimentally
measured QB values for the protein of interest and to generate MEU values that provide information on the oligomeric
state of the receptor of interest. In addition, QB values are used to quantify the density of the fluorescent label, often
presented as receptors per mm2 [9]. Clearly, it is important that the fluorescent label chosen to tag the GPCR of interest
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Muscarinic acetylcholine
receptors: a small family of five
GPCRs whose endogenous ligand is
acetylcholine.
Quantal brightness (QB): average
value assigned by the SpIDA
software to the relative brightness of
an RoI within a cell expressing a
fluorescently labelled protein.
Secretin receptor: a GPCR for
which the endogenous ligand is the
27-amino-acid secretin peptide.
Serotonin 5-hydroxytryptamine
2C (5-HT2C) receptor: also known
as 5-hydroxytryptamine receptors,
this family of 16 GPCRs (and also a
single ligand-gated Na+/K+ cation
channel) is found in the central and
peripheral nervous systems. They
mediate both excitatory and
inhibitory neurotransmission.
SNAP-Tag: self-labelling protein tag,
based upon the DNA repair enzyme
O-6-methylguanine-DNA
methyltransferase. Covalently
interacts with benzylguanine-linked
species that allow incorporation of
molecules of interest, including
fluorescent dyes.
Spatial intensity distribution
analysis (SpIDA): an approach and
image analysis tool for determining
the oligomerisation state of a
fluorescently labelled protein.
Super-Poissonian distribution
function: a probability distribution
having a larger variance than a
Poisson distribution but with the
same mean value.
defines the pharmacology and function of members of the family of glutamate-like or class C
GPCRs [12]. Furthermore, a considerable number of studies have been directed at defining the
quaternary structure of class B GPCRs, with particular focus on the secretin receptor.
Mutagenesis studies and the use of peptides corresponding to each of the transmembrane
domains (TMs) of the secretin receptor resulted in the conclusion that it exists as a dimer
does not have inherent tendency to form dimer/oligomers. The web based osFP server (http://codes.bio/osfp/) [45]
offers information of this topic and tendency to oligomerise may also be determined as described by Cranfill et al. [46].
Appropriate software to perform SpIDA may be downloaded, in the form of a MATLAB graphical user interface
programme, from https://neurophotonics.ca/software. Detailed instructions explaining how to operate the SpIDA
software can be obtained by downloading the user guide manual from the neurophotonics website. Briefly, this
software runs the SpIDA analysis on the RoIs drawn on the input image and generates an Excel compatible text file
containing the various analysed numerical parameter output values, along with a reference output image displaying the
RoI analysed and fitted curve through the histogram plot.
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Figure I. Monomeric EGFP Expression and Localisation to the Plasma Membrane. Schematic representation
of a single molecule of mEGFP or a tandem construct of two molecules of mEGFP linked by a short polypeptide. Each
was fused to the carboxyl-terminal tail of CD86 (A, i), or to a palmitoylation + myristoylation sequence, derived from the
Lyn non-receptor tyrosine kinase, (B, i) and expressed. Laser scanning confocal images of cells expressing a single
mEGFP linked to CD86 (A, ii section and A, iii basolateral membrane) or the palmitoylation + myristoylation sequence (B,
ii section and B, iii basolateral membrane). Representative images are shown. Abbreviation: mEGFP, monomeric
enhanced GFP.
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Figure 1. SpIDA Procedure. Schematic representation of the procedure to perform SpIDA measurements as described
in Box 1 and in more detail in Ward et al. [9]. (A) The G protein-coupled receptor of interest is modified by the incorporation
of a fluorophore, for example, monomeric (A206K) enhanced GFP (i) or the SNAP-tag (ii), for which labelled substrates are
available [43,44], at the carboxyl (intracellular) or amino (extracellular) terminus of the receptor, respectively. (B) The
receptor construct is expressed stably in a heterologous mammalian cell system such as Flp-In T-REx 293 or CHO-K1
cells. (C) Laser scanner confocal images are collected from the glass coverslip attached to the basolateral membrane of
the cells. (D) RoIs (red square) are selected and analysed using MATLAB graphical user interface programme. (E) Mean
fluorescence intensity and QB values are normalised to the QB of the fluorophore label in its monomeric state and provides
information on the density (expressed as particles per mm2) and the oligomeric state (expressed as MEUs) of the
fluorophore-tagged protein. (i) The expression levels and calculated oligomeric state of human dopamine D3 receptor
linked to mEGFP (hD3–mEGFP) expressed in Flp-In T-REx 293 cells is shown as an example [7]. The vertical broken line
corresponds to the mean receptor number per mm2 and the horizontal dotted line corresponds to 1.406 MEU which
represents mean +2 standard deviations of the data set (see Marsango et al. [7] for details). (ii) RoIs characterised by QB
MEU values >1.406 were considered to contain a prevalence of hD3–mEGFP in a dimeric/oligomeric state. Data are
adapted from Marsango et al. [7]. Abbreviations: mEGFP, monomeric enhanced GFP; MEU, monomeric equivalent unit;
QB, quantal brightness; RoI, region of interest; SpIDA, spatial intensity distribution analysis.
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stabilised by interactions that occur between residues in TM IV [13,14] of each protomer.
Interestingly, disruption of the dimeric quaternary structure of the secretin receptor was found
to correlate with reduced potency of secretin to stimulate intracellular cAMP production [13],
and the idea that disruption of signalling effectiveness by altering the quaternary structure of
other GPCRs is a driver for better understanding of the basic rules that define such interactions.
Unlike class C GPCRs, even the existence, and certainly the relevance, of dimers and/or higher-
order oligomers of members of the rhodopsin-like or class A family of GPCRs is still subject to
debate. Although class A receptors can be purified as monomers and, when reconstituted as
monomers, be shown to be functional [15,16], there is increasing evidence to indicate that
these receptors can interact to form dimers and higher-order oligomers and that this property
can influence various aspects of receptor signalling such as trafficking, ligand binding, G protein
coupling, and internalisation from the cell surface [11,17–21]. Despite this expanding body of
knowledge, there are key questions about the mechanism and roles of class A GPCR
dimerisation that remain unresolved. Examples include the extent of such interactions, whether
this is controlled by receptor expression levels, and the stability of such receptor complexes.
Indeed, evidence from different studies has often resulted in distinct views on the extent of
quaternary organisation for a single specific receptor. For example, while some studies have
suggested that the M2 muscarinic acetylcholine receptor exists in multiple coexisting and
interchanging states, in which monomers predominate at steady state [22], other reports
suggest that this receptor exists predominantly, if not exclusively, as dimers [23] or even as
tetramers [24–27]. Moreover, while some studies have concluded that protomer–protomer
interactions are stable over a broad range of receptor expression levels [23,28], others have
provided data to suggest that increases in receptor density lead to an increase in the size of
receptor complexes as a result of transient protein–protein interactions [5,7,8,29,30]. This is
consistent with the concept that mass action may play a fundamental role in defining the
quaternary structure of these transmembrane proteins [5,7,8,29,30]. Recently, each of these
topics has begun to be addressed using SpIDA [1,5–9].
The first example of analysis of GPCR quaternary structure using SpIDA was essentially a proof-
of-concept study, because it was previously well established that the functional GABAB
receptor is a heterodimeric complex formed between coexpressed but distinct GABABR1
and GABABR2 subunits [11]. This study explored the quaternary arrangement of immunocy-
tochemically stained GABAB receptors in sections of rat spinal cord [1]. Performed over a broad
range of receptor density, this revealed the presence of identified dimers only when both
GABABR1 and GABABR2 subunits were labelled with subunit-specific primary antibodies and
detected with the same Alexa-488 fluorophore-conjugated secondary antibody while, by
contrast, only monomers were observed when only one of the subunits was labelled [1]. This
study established that SpIDA could be used as a tool to characterise the quaternary arrange-
ment of other GPCRs for which less is known about either the extent or the molecular basis of
dimerisation.
Milligan and collaborators have subsequently made extensive use of SpIDA measurements to
define the quaternary arrangement of exemplars of both class A [5–7] and class B [8] receptors.
For all such studies, clearly delineated monomeric and dimeric control constructs are required
to define values for QB of the fluorophore of interest, as this is integral to subsequent analysis. In
various studies these have included both single molecules and tandemly organised pairs of
monomeric enhanced GFP (mEGFP) targeted to the plasma membrane by a linked
palmitoylation + myristoylation peptide sequence, or the equivalent forms of mEGFP linked
to the C-terminal region of the monomeric, single transmembrane domain protein CD86
(Box 1 and Figure 1). To ensure the monomeric state of EGFP within tagged constructs it
is routine to introduce an Ala206Lys mutation [31]. Initially, the quaternary structure of the
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serotonin 5-hydroxytryptamine 2C (5-HT2C) receptor was assessed [5]. Herein, the
receptor was modified at the carboxy-terminal tail by in-frame fusion of Ala206Lys mEGFP.
Following introduction of this construct into the inducible locus of Flp-In T-REx 293 cells
[5,32], varying concentrations of the antibiotic doxycycline were used to promote expression of
different levels of the receptor. SpIDA measurements were then performed on RoIs selected in
laser scanning confocal images of the basolateral membrane of such cells. This analysis
indicated the receptor to be present in multiple states ranging from monomers to higher-order
oligomers and that quaternary complexity of 5-HT2C–mEGFP increased markedly with receptor
density, such that the receptor was organised mainly as dimers and higher-order oligomers at
the highest level of expression assessed [5]. These results were different to conclusions
reached using FCS with PCH, which indicated that the same molecular construct as used
above was dimeric across a broad range of expression levels [23]. However, the conclusion
that class A GPCRs vary in organisational structure with expression level has also been
supported for other receptors by others using different approaches [29,30]. Using single-
molecule sensitive total internal reflectance fluorescence microscopy (TIRF-M) analysis of
fluorescently-labelled SNAP-tagged b1- and b2-adrenoceptors, Calebiro and collaborators
[29] concluded that both receptors can be present in mixtures of complexes of different sizes
and that the complexity of the quaternary structure increased with receptor density as a result of
transient receptor–receptor interactions (lifetime was estimated to be 4 s at 20 C). In particular,
the effect of receptor expression on receptor complexity for the b1-adrenoceptor indicated it to
be mainly monomeric at low particle density (70:30 monomer:dimer ratio) whereas for the b2-
adrenoceptor dimers constituted 60% of the total at similar receptor levels, and at higher levels
it was predominantly dimeric with a small proportion of tri/tetramers at the highest receptor
density assessed [29]. Similar conclusions have been drawn from single molecule analysis of a
fluorescently labelled, SNAP-tagged (Figure 1A) version of the D2 dopamine receptor [30].
Two other studies using SpIDA have also shown increasing quaternary organisation with higher
levels of receptor density. The first of these focused on the human D3 dopamine receptor [7].
Following constitutive expression in Flp-In T-REx 293 cells of a C-terminally mEGFP-tagged
form of the human D3 dopamine receptor (hD3R-mEGFP), three clones that showed varying
levels of receptor expression, as assessed by both western blot analysis of cell lysates and
specific binding of the radiolabelled antagonist [3H]spiperone, were studied in detail [7]. SpIDA
measurements on confocal images taken from the basolateral membrane of cells from each
clone showed in each case that, at steady state, a substantial proportion of the RoIs contained
receptors predominantly in dimeric/oligomeric states. Interestingly, the dimer to monomer ratio
was greatest at the cell surface of the clone with the highest hD3R expression level [7]. To
exclude that this was not simply an issue of clonal variability cells from a single clone were
treated with sodium butyrate; a strategy known to increase the expression level of a number of
other GPCRs [33,34]. This increased expression of hD3R-mEGFP by 60% and was associated
with a substantial increase in the proportion of RoIs in which the receptor was organised
predominantly in dimeric/oligomeric states [7]. This approach was also used in the study of
oligomerisation of the class B secretin receptor [8]. As stated above, previous studies [13,14]
described the wild-type secretin receptor as existing predominantly if not exclusively in a
dimeric state, but that a monomeric state was favoured by the introduction of two single point
mutations (Gly243Ala and Ile247Ala) into TMIV of the receptor [13,14]. To gain further insights into
the basis of oligomerisation of the secretin receptor and to assess the proportion of the receptor
that might be dimeric, Ward and collaborators performed SpIDA measurements on the baso-
lateral membrane of CHO-K1 cells stably expressing either wild-type or the Gly243Ala-Ile247Ala
mutated secretin receptor; both modified at the carboxyl terminus by addition of mEGFP [8].
This analysis showed that although both types of receptor were expressed at equivalent levels,
the quaternary organisation of the wild-type and mutated receptors was different. In particular,
although the wild-type secretin receptor was found to be largely dimeric, this was not complete
as had been suggested by Harikumar and collaborators [13]; a substantial fraction was
180 Trends in Pharmacological Sciences, February 2018, Vol. 39, No. 2
monomeric (Figure 2A). By contrast, and indeed as predicted by Harikumar et al. [13], the
Gly243Ala-Ile247Ala secretin receptor was recorded to be almost entirely monomeric, with only
some 10% being scored as dimeric [8]. Treatment of cells expressing either the wild-type
(Figure 2A) or the Gly243Ala-Ile247Ala secretin receptor with sodium butyrate substantially
increased expression level of both forms as assessed by both immunoblotting and fluores-
cence analysis of confocal images [8]. QB analysis of RoIs from the basolateral membrane of
cells showed that sodium butyrate treatment also modified the quaternary structure of the wild-
type receptor by increasing its organisational complexity such that >20% of the observations
were now scored as oligomeric rather than dimeric (Figure 2A). By contrast, an equivalent effect
on the quaternary organisation of the Gly243Ala-Ile247Ala secretin receptor variant was not
observed [8]. These studies also assessed the potential contribution of G protein availability to
steady-state receptor dimerisation. Extensive downregulation of the a subunit of Gs (the G
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Figure 2. Effect of Expression Level and Ligand Treatment on GPCR Quaternary Structure. (A) The oligomeric
state of the secretin receptor–mEGFP expressed in untreated CHO-K1 cells (blue) or cells treated overnight with 5 mM
sodium butyrate (yellow). Vertical broken lines represent mean receptors per mm2 for control and sodium-butyrate-treated
cells. The horizontal dotted lines represent 1.48 and 3.0 MEU respectively (see Ward et al. [8] for determination of these
values). RoIs characterised by QB MEU >1.48 were considered to contain a prevalence of secretin–mEGFP receptor in
larger than monomeric state, while those characterised by QB MEU >3.0 were considered to contain a prevalence of
secretin–mEGFP receptor in an oligomeric, rather than dimeric, state. Proportions of outcomes corresponding to
monomer, dimer, or oligomer are shown. Data are adapted from Ward et al. [8]. (B) The oligomeric state of hD3R–
mEGFP expressed as QB MEU in HEK293 derived cells untreated (grey) or treated overnight with 10 mM spiperone (yellow)
or haloperidol (blue) is shown. Vertical broken lines represent the mean receptor per mm2 for untreated and treated cells (i).
RoIs characterised by QB MEU >1.406 were considered to contain a prevalence of hD3R–mEGFP in a dimeric/oligomeric
state (ii). Data are adapted from Marsango et al. [7]. Abbreviations: mEGFP, monomeric enhanced GFP; hD3R, human
dopamine D3 receptor; MEU, monomeric equivalent unit; NT, not treated; QB, quantal brightness; RoI, region of interest.
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protein that transduces signal via the secretin receptor to elevation of cAMP levels) did not
modulate the extent of dimerisation [8], indicating no key role for the G protein in defining
receptor quaternary structure.
Using SpIDA to Examine Potential Ligand-Induced Alterations of GPCR
Quaternary Structure
The most basic and fundamental aspects of GPCR-regulated physiology are driven by the
interactions between the receptor and the ligand to which it binds and how this regulates
signalling cascades. If the extent of receptor oligomerisation is an important element in the
control of responses to either endogenous ligands or synthetic medicines and drugs, then it
might be anticipated that this could be altered by ligand binding.
In extending SpIDA-based analysis of the steady-state level of oligomerisation of the human 5-
HT2C receptor, it was observed that treatment of cells expressing 5-HT2C–mEGFP with several
compounds with antagonist/inverse agonist function at this receptor promoted its monomer-
isation [5]. Importantly, this effect was time dependent and was reversed following washout of
the ligands, resulting in restoration of the initial oligomeric organisation [5]. In these studies
reversal of the effect of the ligands was assessed 60 min after washout but rate of dissociation
of the ligands was not assessed and, as their affinity for the 5-HT2C receptor is high, then ligand
‘off-rate’ could be anticipated to be slow. Future studies should consider using ligands with
rapid dissociation rates and attempt to define if quaternary structure is restored rapidly following
ligand dissociation. Only three ligands were assessed in these studies and, because two of
these were closely related structurally, further studies should also explore a greater diversity of
chemotypes. This may be illuminating because in equivalent studies using a broader range of
antagonist/inverse agonist ligands at the hD3R, as well as identifying ligands that promoted
monomerisation of the receptor, several ligands were shown to produce no effect on the
monomer/dimer ratio (Figure 2B), [7]. Specifically, both spiperone and haloperidol favoured the
monomeric state of the receptor, and this effect was both concentration dependent and, like for
the 5-HT2C receptor, reversed upon washout of the drug [7]. One surprising and currently
unexplained feature of the effect of spiperone was whilst the induced monomerisation of the
receptor was concentration dependent, half-maximal effect required higher concentrations of
spiperone than predicted to produce half-maximal receptor occupancy [7]. This clearly requires
further analysis but could potentially reflect a much-discussed concept [35–37] whereby
binding of spiperone to a hD3R dimer could display significant negative cooperativity, where
binding of the first molecule of spiperone would reduce the affinity of a subsequent molecule of
spiperone to bind to the second orthosteric pocket. In this situation the observed potency of
spiperone suggests that each of the orthosteric binding sites needs to be occupied prior to
induced receptor monomerisation. Importantly, the requirement for the receptor to bind (at
least one molecule of) spiperone to induce monomerisation has already been demonstrated.
Asp110Ala hD3R is unable to bind spiperone with significant affinity [7]. However, while this
mutation did not affect the steady-state extent of dimerisation compared to the wild-type
receptor observed at equivalent expression levels [7], treatment of cells expressing this mutant
with spiperone did not induce monomerisation of Asp110Ala hD3R–mEGFP [7].
Unlike spiperone and haloperidol, ligands including eticlopride, the structurally closely related
ligand nemonapride, and clozapine had no effect on the oligomeric structure of hD3R–mEGFP
[7]. To attempt to provide a molecular basis for these observed differences a combination of
ligand docking studies and molecular dynamics simulations were used [7]. These suggested
that binding of spiperone induces an increase in the distance between reference a-carbon
atoms in TMs IV and V, while binding of haloperidol increases the distance between reference
a-carbon atoms in TMs I and II but not those in TMs IV and V [7]. Such studies highlight that
there must be multiple inactive conformations of a GPCR, and that distinct receptor
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antagonists/inverse agonists favour different inactive conformations (in a similar vein to the idea
that different agonist ligands may stabilise distinct active conformations). Although simply
correlative at this point, mutagenesis studies designed to define the key regions of TM domains
involved in dimerisation of hD3R have indicated important contributions of residues within each
of TMs I, II, and IV and V [38] (see Box 2 for discussion on the molecular basis of GPCR
quaternary structure). That not all antagonist/inverse agonist ligands at the hD3R induce
measurable alterations in steady-state dimerisation/oligomerisation of this receptor suggests
that a more broad-ranging analysis of potential effects of clinically used and trialled antipsy-
chotic drugs would be of interest, as would correlations of their effects on hD3R, and potentially
D2-dopamine receptor, organisation with other clinical parameters.
If certain ligands induce monomerisation of hD3R and the 5-HT2C receptor then there is no
intrinsic reason to assume that other ligands, maybe at different GPCRs, could not increase
quaternary complexity. Although systematic consideration is lacking, it is becoming established
that the extent of dimerisation differs between class A GPCRs expressed at similar levels and in
the same cellular background. This was made explicit by Calebiro et al. [29] when comparing
b1- and b2-adrenoceptors. SpIDA of the human muscarinic M1 (hM1) and hM3 receptors
revealed both to be present predominantly as monomers at the cell surface, although a
significant fraction of dimers was also observed [6]. Sustained treatment of cells expressing
M1R–mEGFP with the selective M1R antagonist/inverse agonist pirenzepine, or the structurally
related ligand telenzepine, resulted in both a marked increase in the density of the receptor and
in the percentage of RoIs within which the receptor was organised predominantly as dimers/
oligomers [6]. Enhanced organisational structure might simply have resulted from the enhanced
level of expression and the effect of mass action. However, with M1R–mEGFP cloned into the
antibiotic inducible locus of Flp-In T-REx 293 cells, levels of M1R–mEGFP expression in the
basolateral membrane of vehicle-treated cells could be titrated to be akin to those present in
Box 2. GPCR Quaternary Structure
Because GPCRs are characterised by poor protein stability when removed from the lipid-rich environment of a
membrane and can assume multiple conformational states, structural studies are challenging. Recently, however,
extensive optimisation of crystallisation conditions (i.e., introduction of fusion partners and single point mutations,
addition of selective ligands or antibodies during protein purification and crystallisation) has resulted in variants with
markedly increased stability more suitable for crystallographic studies and, to date, >130 GPCR structures have been
resolved [47]. In some of these, the receptors were revealed as parallel dimers and/or tetramers suggesting the
existence of different dimer interfaces for different GPCR homodimers [48–56]. These structures showed rather
conserved contact interfaces involving TMI, II and intracellular helix VIII as observed in the b1-adrenoreceptor [51],
m- and k- opioid receptors [48,50], rhodopsin [54,55], and opsin [56]. By contrast, less conserved interfaces were
observed on the other side of the receptor TM bundle, with TMIV–V interactions observed in b1-adrenoreceptor [51], the
smoothened receptor [52], and the adenosine A1 receptor [53]; TMV–VI interactions observed in the m-opioid receptor
[48]; and mainly TMV–TMV interactions, with contributions of residues also from the first intracellular loop, observed in
the chemokine CXCR4 receptor [49].
It is clearly possible that some of these observed interfaces reflect crystal packing artefacts rather than defining
physiologically relevant dimer interfaces. As such, distinct approaches are required to support or validate such ideas. As
well as a vast range of studies that have explored protein–protein interactions via imaging and resonance energy
transfer-based methods [57], predictions from atomic level structural studies have been assessed via both chemical
crosslinking and mutagenesis. For example, the two crystallographic interfaces of the b1-adrenoreceptor were
confirmed to be relevant via receptor crosslinking studies [51]. Furthermore, combinations of molecular modelling,
mutagenesis and resonance energy transfer studies have been used to assess the human D3 dopamine receptor
organisational structure shown to be akin to that of the b1-adrenoreceptor dimeric structures [38]. The same approach
has also been used to define the interfaces that allow M3 muscarinic acetylcholine receptor dimer interactions [58] and
resulted in conclusions broadly in agreement with work of others based on both chemical crosslinking experiments
[59,60] and wide ranging, unbiased mutagenesis studies [61]. Finally, contributions of residues within TMI–II–IV–V and
helix VII have also been described in studies using cysteine crosslinking that were designed to explore the basis of D2
dopamine receptor homodimer formation [28,62,63]. The existence and potential pharmacological and physiological
relevance of GPCR quaternary structure has been reviewed extensively [11,20,21].
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pirenzepine-treated samples. SpIDA measurements then showed pirenzepine treatment to
have enhanced the proportion of M1R dimers independent of receptor upregulation [6].
Although little discussed by later commentators, Ilien et al. [39] had earlier used a fluorescence
resonance energy transfer (FRET)-based approach to also show an enhanced proportion of
M1R dimers to be generated rapidly upon binding of pirenzepine. As for the hD3R, not all
muscarinic antagonists were able to mimic the effect of pirenzepine and telenzepine, as neither
atropine nor N-methylscopolamine did so [6]. A molecular understanding of these differences
remains to be defined. Even closely related receptors can show substantial differences in
ligand-induced alterations in quaternary structure. The M3 muscarinic receptor is also able to
bind both pirenzepine and telenzepine (although with significantly lower affinity than hM1R).
However at saturating concentrations, neither of these ligands modified the quaternary struc-
ture of hM3R [6]. Clearly, further work is required to understand the basis of these differences.
To date, virtually all SpIDA-based studies on ligand regulation of GPCR quaternary structure
have centred on antagonists/inverse agonists. It might be anticipated that agonist ligands could
also alter receptor quaternary structure. Indeed, as proof of concept that this can be monitored
and quantified, in a different receptor class, a series of studies have shown that in Flp-In T-REx
293 cells induced to express the epidermal growth factor receptor (EGFR) linked to mEGFP
addition of EGF results in rapid transition of the receptor construct from being predominantly
monomeric to being largely dimeric [5,8,40]. However, this did not occur when using a mutant
receptor unable to bind EGF effectively [8]. However, only in the case of the secretin receptor
has SpIDA been used to date to assess if short-term agonist treatment alters quaternary
structure of a GPCR. Here, secretin treatment for a 10-min period did not invalidate the use of
SpIDA but no significant agonist effect on receptor organisation was detected [8]. To extend the
study of agonist effects on GPCR oligomeric structure, several potential approaches to
overcome issues such as internalisation of GPCRs are likely to be used in the near future.
An example is the use of cellular systems in which b-arrestins, which play key roles in clathrin-
dependent endocytosis, have been eliminated by genome editing [41].
Concluding Remarks
In this article a brief description of procedures used to perform SpIDA measurements has been
given, followed by a detailed description of studies conducted to date in which SpIDA has been
used to investigate the oligomeric organisation of GPCRs and its regulation. Such studies have
provided new insights into this contentious issue, but many challenges remain (see Outstanding
Questions); both in terms of further development of SpIDA, and how information from such
studies can be combined with other imaging modalities and/or with approaches, including
molecular dynamics simulations of ligand interactions with GPCRs. Given the significant
interest in the potential existence of heteromeric GPCR complexes, the development of
two-colour SpIDA has recently been described by Godin and co-workers [42], and this is
likely to be useful in addressing proportions of GPCR homomers and heteromers present in a
sample that coexpresses a compatible pair of GPCRs. Importantly, because SpIDA is based on
analysis of simple confocal images, and these can be derived from fixed cells and tissues, it
should be possible to perform SpIDA measurements more routinely on tissue sections from
mice and other model organisms expressing mEGFP, or other wavelength-shifted, fluoro-
phore-tagged GPCRs of interest. In this way GPCR oligomerisation state could be explored in
physiologically relevant settings and contexts, in animal models of disease or following the
administration of therapeutic drugs.
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Outstanding Questions
Does Agonist Binding Modify
Receptor Quaternary Structure?
In general, agonists promote receptor
clustering and internalisation, making
confocal images difficult to analyse by
SpIDA. Consequently, either the time
of treatment with ligand must be lim-
ited or alternative approaches such as
expression in cell lines genome edited
to prevent agonist-induced internalisa-
tion and/or clustering of receptors to
clathrin-coated pits could be adopted.
What Role Does G Protein-Cou-
pling Play in Defining GPCR Qua-
ternary Structure?
Few studies have focused on the
mechanisms of interaction between
the protomers of a GPCR oligomeric
complex and G proteins, and it is
unclear whether GPCR quaternary
structure is affected or defined by G
protein coupling. SpIDA could be per-
formed on cells previously treated with
molecules that inhibit G-protein cou-
pling or are genome edited to lack
expression of specific or multiple G
proteins.
Can SpIDA Be Used to Study the
Kinetics of Formation and Stability
of GPCR Oligomers?
SpIDA could be used, in combination
with other methods such as TIRF-M, to
obtain information about protomer–
protomer association and dissociation
constants.
Can SpIDA Be Used to Detect and
Quantify GPCR Hetero-oligomers?
To date, SpIDA has only been used to
observe and quantify GPCR homo-
oligomers. However, two-colour
SpIDA [42], using pairs of fluorescent
proteins with similar excitation but dif-
ferent emission wavelengths, is being
developed and is likely to allow con-
current detection and quantification of
homo- and hetero-oligomeric
interactions.
Can SpIDA Be Used to Monitor
Receptor Quaternary Organisation
in Native Tissues?
Although already reported using fluo-
rescent antibody labelling, SpIDA can
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